Aflibercept continues to play a major role in the global ophthalmology therapeutics market, particularly in the treatment of retinal vascular diseases such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Between 2023 and 2026, the market witnessed significant regulatory progress and product expansion driven by the higher-dose formulation, Eylea HD.
In August 2023, the U.S. Food and Drug Administration (FDA) approved Eylea HD® (aflibercept) Injection 8 mg, developed by Regeneron Pharmaceuticals, for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. This approval represented a major advancement in anti-VEGF therapy because Eylea HD introduced a higher-dose formulation of aflibercept designed to maintain efficacy while reducing injection frequency for patients.
Aflibercept functions as a vascular endothelial growth factor (VEGF) inhibitor by blocking VEGF-A and placental growth factor (PlGF), both of which are involved in abnormal blood vessel formation and leakage in retinal diseases. By reducing vascular permeability and suppressing abnormal angiogenesis, aflibercept helps preserve vision and slow disease progression in multiple chronic eye disorders.
The approval of Eylea HD was supported by positive results from the pivotal PULSAR and PHOTON Phase 2/3 clinical trials. These studies demonstrated that the 8 mg formulation achieved vision improvements comparable to standard Eylea treatment while enabling extended dosing intervals with fewer injections. Reduced treatment burden has become an important factor in retinal disease management, particularly among elderly and diabetic populations requiring long-term therapy.
In 2025, the aflibercept market experienced additional regulatory momentum. In August 2025, Regeneron announced that the FDA extended the review period for two Eylea HD regulatory submissions, including a supplemental Biologics License Application (sBLA) for the treatment of macular edema following retinal vein occlusion and expanded monthly dosing schedules across approved indications. The company also submitted a Chemistry, Manufacturing and Controls (CMC) Prior Approval Supplement related to the Eylea HD prefilled syringe presentation. These developments reflected ongoing efforts to expand product convenience, dosing flexibility, and clinical utility.
Later in November 2025, the FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion (RVO) and also approved monthly dosing across existing indications. The approval was supported by results from the Phase 3 QUASAR trial, where Eylea HD demonstrated non-inferior visual acuity improvements compared to standard Eylea dosing regimens while maintaining extended treatment intervals.
In April 2026, Eylea HD achieved another major milestone when the FDA approved dosing intervals of up to five months for patients with wet age-related macular degeneration and diabetic macular edema. This made Eylea HD the first and only injectable anti-VEGF therapy with such extended dosing intervals for these conditions. Long-term data from the PULSAR and PHOTON studies showed that many patients maintained visual and anatomical improvements even with significantly fewer injections over time.
Overall, the Aflibercept market (2023–2026) reflects strong innovation in retinal therapeutics, with increasing focus on reducing treatment burden, improving patient adherence, and extending dosing intervals. Continued FDA approvals and expanded indications for Eylea HD are expected to strengthen aflibercept’s position in the competitive ophthalmology market while supporting long-term growth in anti-VEGF therapies.
